M&L Healthcare Investments
VC Fund
Singapore, Singapore
M&L Healthcare Investments is a VC fund in Singapore focused on Medical Device and Medical. M&L Healthcare Investments provides and offers financial assistance to businesses from the healthcare industry. It focuses on investing in businesses that promote medical therapies and create medical technologies. and M&L Healthcare Investments is based in Singapore.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 22%
Last updated:
For AI agents: llms.txt
Industries M&L Healthcare Investments invests in
Stages M&L Healthcare Investments invests in
Countries M&L Healthcare Investments invests in
Round sizes
Round size
- Series A
- $4.7M–$6.3M
- Series B
- $42M–$48M
- Series C
- $40M–$80M
Investment Focus
Industry
- Medical Device 8 (89%)
- Medical 4 (44%)
- Health Care 4 (44%)
- Neuroscience 1 (11%)
- Biotechnology 1 (11%)
Stage
- Series C 3 (33%)
- Series A 2 (22%)
- Series B 2 (22%)
- Seed 1 (11%)
- Funding Round 1 (11%)
Country
- France 3 (33%)
- United States 3 (33%)
- Singapore 1 (11%)
- Switzerland 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Endovascular Engineering is a medical technology company focused on developing and deploying advanced clot removal solutions for the treatment of venous thromboembolism. It specializes in thrombectomy technologies designed to improve clinical outcomes and procedural efficiency in minimally invasive vascular interventions. The company’s flagshipinnovation is the Hēlo™ Thrombectomy System, a catheter-based device that uses a combination of mechanical agitation and physician-controlled aspiration to remove blood clots. Its technology emphasizes features such as a self-expanding funnel design and dual-action functionality to enhance clot engagement and navigation through complex anatomies. Endovascular Engineering primarily serves healthcare providers, including interventional cardiologists and radiologists, supporting the treatment of conditions such as pulmonary embolism and deep vein thrombosis. | $80M / Series C / Apr 07, 2026 | ||
| SafeHeal is the first company created and incubated by MD Start, a medtech accelerator developing innovative medical devices based on inventions from physicians. It is currently funded by MD Start and Sofinnova Partners. SafeHeal is laureate of the Worldwide Innovation Challenge 2015 edition (Concours Mondial de l’Innovation - Phases 1 and 2) andof the iLab grant program, which foster talent and bring out future champions of the French economy.SafeHeal was also elected as the most promising and innovative investor conference MedTech start-up at Biovision 2016, was a finalist for the global Medtech Innovator 2016 competition.Finally, SafeHeal is a 2016 recipient of the Charles Foix grant which rewards innovations aimed at improving the quality of life of elderly people. | $39.9M / Series C / Apr 29, 2025 | ||
| Endovascular Engineering is a medical technology company focused on developing and deploying advanced clot removal solutions for the treatment of venous thromboembolism. It specializes in thrombectomy technologies designed to improve clinical outcomes and procedural efficiency in minimally invasive vascular interventions. The company’s flagshipinnovation is the Hēlo™ Thrombectomy System, a catheter-based device that uses a combination of mechanical agitation and physician-controlled aspiration to remove blood clots. Its technology emphasizes features such as a self-expanding funnel design and dual-action functionality to enhance clot engagement and navigation through complex anatomies. Endovascular Engineering primarily serves healthcare providers, including interventional cardiologists and radiologists, supporting the treatment of conditions such as pulmonary embolism and deep vein thrombosis. | $42M / Series B / Feb 18, 2025 | ||
| FastWave Medical is an early-stage medical device company. | $19M / Dec 16, 2024 | ||
| CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complicationrates in these patients. | $48.5M / Series B / Sep 10, 2024 | ||
| HEPTA Medical develops a sensor, embedded into a bronchoscopic or percutaneous ablation catheter, which provides temperature-based feedback. This enables real-time dosing to precisely target and ablates pulmonary nodules, the precursor of lung cancer, without the need for surgery or radiation. | $6.3M / Series A / Sep 04, 2024 | ||
| The CorWave LVAD utilizes an undulating disc wave pumping mechanism, replacing the high speed, high shear impeller of current continuous flow rotary pumps. The result is much less trauma to the blood, reducing clotting and bleeding complications. The high frequency actuation of the Corwave pump provides for pulsatile flow that mimics the action ofthe native heart. Current LVADs provide only continuous flow with no significant pulsation, due to the high inertia of their rotors. Its low power consumption and small size will facilitate totally implantablity with the incorporation of a wireless energy transfer system. | $43.2M / Series C / Jan 06, 2021 | ||
| Pedra Technology has developed the world’s first intra-operative monitor for real-time blood perfusion assessment which addresses a critical need in the peripheral vascular disease (PVD) market. PVD affects over 20 million people in the US, over 80 million people in China, and represents a multi-billion dollar opportunity. Without proper care PVDcan lead to limb ischemia and amputations. Chronic wounds or ulcers on the feet (unable to heal after 8 weeks due to poor blood flow) are treated with balloon angioplasty to re-open blocked blood vessels in the legs. During such procedures, the Pedra device gives the physician intra-operative instantaneous feedback on blood perfusion of foot tissue. It is this blood perfusion at the tissue level that is critical for wound healing. This is the first time that physicians, using the Pedra device, are able to achieve an accurate objective and quantitative measure of blood perfusion while the patient is still in the operating theater. No other technology does this, as X-ray angiograms only image macrovascular blood flow, which can lead to misleading conclusions, resulting in adverse outcomes or repeat procedures. | $4.7M / Series A / Sep 22, 2020 | ||
| UroDev Medical designs devices to improve the quality of life for people with Spinal Cord Injury and Disease. Their first product, The Connected Catheter, will revolutionize the way millions of people deal manage their bladders. | $2.5M / Seed / Apr 05, 2019 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does M&L Healthcare Investments invest in?
M&L Healthcare Investments invests primarily in Medical Device, Medical and Health Care startups, most often at Series C and Series A stage. Most of the 9 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is M&L Healthcare Investments's check size?
M&L Healthcare Investments typically joins rounds of $4.7M–$6.3M at Series A, $42M–$48M at Series B and $40M–$80M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds M&L Healthcare Investments participates in.
When did M&L Healthcare Investments last invest?
The most recent investment recorded for M&L Healthcare Investments closed in Apr 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
